Low molecular weight heparin is safe and effective in the treatment of deep venous thrombosis (1,2):
A meta-analysis has concluded that, in patients with acute venous thromboembolism, fixed dose subcutaneous low molecular weight heparin is more effective at reducing the incidence of symptomatic recurrent venous thromboembolism, major haemorrhage, and all cause mortality, than adjusted dose unfractionated heparin (3).
However note that a randomised open-label trial of 708 patients aged 18 years or older with acute venous thromboembolism revealed that fixed-dose subcutaneous unfractionated heparin was as effective and safe as low-molecular-weight heparin in patients with acute venous thromboembolism and is suitable for outpatient treatment (4).
Reference:
Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.